endovascular.es

Título: ArtVentive Medical Receives FDA Clearance for EOSTM Device
Fecha: 04-12-2014
December 04, 2014 03:33 PM Eastern Standard Time
CARLSBAD, Calif.--(BUSINESS WIRE)--ArtVentive Medical Group, Inc. (OTC Bulletin Board AVTD) announced today that it has received U.S. Food and Drug Administration (FDA) clearance for the Endoluminal Occlusion System (EOSTM). Designed for use in the peripheral vasculature, the EOSTM offers immediate, complete and total occlusion in arterial and venous settings.
“I see the EOSTM device as a potential game changer for physicians and their patients”
“I see the EOSTM device as a potential game changer for physicians and their patients,” said Dr. Anthony Venbrux, Interventional Radiologist at The George Washington University Hospital in Washington, D.C. “In my experience with the device, it has shown immediate and complete vascular occlusion upon deployment. The use of this new endovascular technology assures the operator that they have stopped blood flow at the treatment site. This creates an opportunity for shorter procedure times and less radiation exposure to patients and staff in addition to lower medical costs.”
ArtVentive CEO Jim Graham stated, “This is a testament to the hard work and dedication of our entire team. The EOSTM technology platform serves unmet clinical needs and provides a foundation for future innovation to expand into additional treatment areas. We look forward to sharing the technology with physicians in the U.S. and additional international markets as we commence our commercialization efforts.”
“We are excited to introduce the EOSTM device into the U.S. market,” said Dr. Leon Rudakov, President of ArtVentive. “We are expanding our case experience in Europe and anticipate further positive acceptance in the U.S. and global markets.”
About ArtVentive Medical Group, Inc.
ArtVentive Medical Group, Inc., with corporate headquarters in Carlsbad, California, is an innovative, multi- faceted medical device company focused on developing, manufacturing and marketing globally a family of devices featuring the ArtVentive EOSTM.
The ArtVentive EOSTM is catheter-based, self-expandable and facilitates permanent or temporary occlusion of peripheral body lumens, cavities occurring within the body’s vascular system and organ network. The ArtVentive EOSTM is designed to serve as a safe and reliable alternative to major surgery in certain cases. Thistechnological innovation brings current interventional, image-guided techniques to a new level of sophistication, with the potential to resolve significant health issues.
The ArtVentive EOSTM serves as a proprietary technology platform for several major clinical areas, including peripheral and neurological vascular disorders, women’s health (minimally invasive contraceptive and birth control), interventional cardiology, pulmonary and interventional oncology procedures.
More information about ArtVentive can be found at www.artventivemedical.com.
Forward-Looking Statements
This news release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to the Company’s current expectations, projections and beliefs concerning matters that are not historical facts. Forward-looking statements are not guarantees of future performance. Forward-looking statements involve uncertainties, risks, assumptions and contingencies, many of which are outside the Company’s control, and, thus, actual results could differ materially from those described in or implied by any forward-looking statement. All forward-looking statements are based on currently available information and speak only as of the date on which they are made. The Company assumes no obligation to update any forward-looking statement made in this news release that becomes untrue because of subsequent events, new information or otherwise, except to the extent it is required to do so in connection with the Company’s ongoing requirements under federal securities laws. For a further discussion of factors that could cause the Company’s future results to differ materially from any forward-looking statements, see the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission.
Contacts
ArtVentive Medical Group, Inc. H.J. (Jim) Graham, Chief Executive Officer Telephone: 760-471-7700 E-mail: hjgraham@artventivemedical.coma
Fuente: endovascular.es

endovasculares.es